Aspirin in the Prevention of Collapse in Osteonecrosis of the Hip

Osteonecrosis of Femoral Head Clinical Trial

Official title:

Aspirin (Acetylsalicylic Acid) in the Prevention of Collapse of the Femoral Head in Early-stage Non-traumatic Osteonecrosis: a Two-year Multicenter, Prospective, Randomized, Double-blind, Placebo-controlled Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03405974
• Other study ID #: ONFH-ASA2016
• Status: Recruiting
• Phase: Phase 3
• First received: January 14, 2018
• Last updated: January 22, 2018
• Start date: October 12, 2017
• Est. completion date: November 1, 2021

Study information

• Verified date: January 2018
• Source: McGill University Health Center
• Contact: Bouziane Azeddine, Ph.D.
• Phone: 5149341934
• Email: bouziane.azeddine[@]mail.mcgill.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if prolonged administration of low-dose aspirin will prevent the progression of early-stage osteonecrosis of the femoral head and may even reduce the extent of involvement of the femoral head by the necrotic process The design is intended to be parallel group where a total of 114 patients will be randomized in a 1:1 ratio to the treatment (ASA) and the control (Placebo) arms.

Description:

1. TRIAL OBJECTIVES The primary objective of this study is to evaluate the radiologic progression of ONFH on either radiographs or MRI. A successful outcome is defined as no difference in ONFH staging according to the Ficat & Arlet or Steinberg classifications at last patient follow-up compared to initial radiological staging. This translates into lack of progression over the course of the study while the natural evolution is progression over time.

The secondary objective is to evaluate the percentage of involvement of the femoral head on radiographs and/or MRI which measures the extent of the disease. We expect that the extent of the disease will be reduced at 2 years.

2. STUDY DESIGN AND DURATION This study is a multicenter, prospective, randomized, double-blind, placebo-controlled trial that aims to test the efficacy of the proposed medical intervention (ASA). The design is intended to be parallel group where a total of 114 patients will be randomized in a 1:1 ratio to the treatment (ASA) and the control (Placebo) arms.

All patients presenting to the osteonecrosis clinic of one of the participating centres will be first evaluated by an orthopedic surgeon to confirm the diagnosis of early ONFH on at least one hip. Selected patients will be screened for eligibility according to specific inclusion and exclusion criteria.

Eligible patients who accept to participate in this study will be randomized to either a control arm (placebo) or a treatment arm (Aspirin). Recruited patient will take their assigned treatment daily at breakfast from enrolment and for a minimum of two years They will be followed over a period of 2 years. Evaluations will be taken at baseline and every 6 months (5 visits in total).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 114
• Est. completion date: November 1, 2021
• Est. primary completion date: November 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Age 18-60 years old

2. Patients with early osteonecrosis of the hip as defined above

3. Diagnosis confirmed within 3 months of the screening visit

4. Patients accept to take the study medication

Exclusion Criteria:

1. A history of hip trauma or surgery affecting the hip involved with early stage osteonecrosis as per criteria above

2. Concurrent use of anticoagulants

3. Concurrent use of bisphosphonates

4. Concurrent use of Aspirin for any reason

5. Patients with recent active severe peptic ulcer disease that are not on PPI.

6. Patients with advanced osteonecrosis of the hip with signs of collapse or end-stage joint arthritis of the hip that are immediately referred for surgical consultation for THA

7. Patients who are hypersensitive to ASA, salicylates, or non-steroidal anti-inflammatory drugs

8. Hepatic impairment (Bilirubin total, AST, ALT > 2-3x upper limit of normal), renal failure (creatinine level above normal with glomerular filtration rate < 45 ml/minute), or congestive heart failure

9. Platelets number should be more than 100,000 ( > 100 x 109 /L)

10. Pregnancy. If the patient is not sure whether she may be pregnant or not, a screening for pregnancy should be done.

Related Conditions & MeSH terms

• Femur Head Necrosis
• Osteonecrosis
• Osteonecrosis of Femoral Head
• Osteonecrosis; Aseptic, Idiopathic

Intervention

Drug:
• Aspirin
Aspirin (acetylsalicylic acid)
• Placebo
Placebo

Locations

Country	Name	City	State
Canada	McGill University Health Centre	Montreal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
McGill University Health Center

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Albers A, Carli A, Routy B, Harvey EJ, Séguin C. Treatment with acetylsalicylic acid prevents short to mid-term radiographic progression of nontraumatic osteonecrosis of the femoral head: a pilot study. Can J Surg. 2015 Jun;58(3):198-205. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of radiologic progression of osteonecrosis	The primary endpoint is to evaluate the radiologic progression of ONFH by measuring the difference in ONFH staging according to the Ficat & Arlet or Steinberg classifications at last patient follow-up compared to initial radiological staging.	6 months
Secondary	Measure the percentage involvement of the femoral head on MRI.	The secondary endpoint is to measure evolving extent of involvement of the femoral head on radiographs and/or MRI that measures the extent of the disease.	6 months